Breega
European seed and early-stage venture capital firm; co-led BioOrbit's £9.8m seed round.
Last refreshed: 1 May 2026 · Appears in 1 active topic
How is Breega expanding into UK deep-tech from its French base?
Timeline for Breega
Co-led BioOrbit £9.8m seed round
UK Startups and Innovation: BioOrbit raises £9.8m for orbital pharma- What does Breega VC invest in?
- Breega invests in seed and Series A mission-driven technology companies across Europe, with a focus on fintech, health, climate and deep tech. It operates from Paris and London.Source: Breega public record
- Who founded Breega?
- Breega was founded in 2015 by Ben Marrel and Maximilian Bacot, who bring operational and investment backgrounds from Unilever, Goldman Sachs and prior VC experience.Source: Breega public record
- Why did Breega co-lead BioOrbit's seed round?
- Breega co-led BioOrbit's £9.8m round alongside LocalGlobe in April 2026. The round is the world's largest seed for in-space pharmaceutical manufacturing, a sector BioOrbit is pioneering with a UK regulatory pathway published in March 2026.
Background
Breega is a Paris-founded, pan-European venture capital firm focused on seed and Series A investment in mission-driven technology companies. Founded in 2015 by Ben Marrel and Maximilian Bacot, the firm operates across France, the UK, Spain and other European markets, with offices in Paris and London. Its investment thesis emphasises founders pursuing structural problems in fintech, health, climate and deep tech, and the team brings operational experience from Unilever, Goldman Sachs and other institutions alongside venture experience. Portfolio companies include Spendesk, Lunchr and GetAccept.
Breega typically writes initial cheques of €1m-€5m at seed and follows through to Series A in high-conviction bets. The fund has expanded into the UK market progressively as London's deep-tech and health-tech ecosystems have matured, and it participates in cross-border syndicates with UK-based co-investors including LocalGlobe. AUM is estimated at approximately €200m across its funds.
Breega's co-lead on BioOrbit's £9.8m in-space drug manufacturing round in April 2026 alongside LocalGlobe marks the firm's entry into UK space-pharma, a sector enabled by a regulatory pathway jointly published by the UK Space Agency, MHRA, Regulatory Innovation Office and Civil Aviation Authority in March 2026. The round is notable as the world's largest seed for in-space manufacturing.